Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT05612386
  4. Details
NCT05612386 Clinical Trial

Planning Message Recommending Same Time/Location as Last Vaccine

COVID-19 Clinical Trial

Official title:
Planning Message Recommending Same Time/Location as Last Vaccine

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05612386
Other study ID # 851911-Trial E
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 3, 2022
Est. completion date February 6, 2023

Study information
Verified date March 2023
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message suggesting the same day of the week, at the same time of day, and at the same pharmacy location as their last vaccination and a control message telling patients that an updated COVID booster vaccine is waiting for them. The intervention testing if text messages encouraging vaccination by suggesting patients receive a shot on the same day of the week, at the same time of day, and at the same pharmacy location as their last vaccination will produce more vaccinations than otherwise identical messages.

Recruitment information / eligibility
Status Completed
Enrollment 520000
Est. completion date February 6, 2023
Est. primary completion date December 8, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Exclusion Criteria: 1. The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message 2. The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• COVID Booster text messages
Participants will receive text messages per descriptions listed in the arms.

Locations
Country Name City State
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)
Lead Sponsor Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary COVID bivalent booster receipt Whether patients receive a bivalent COVID booster at the pharmacy in question During the 30 days after receiving the SMS/MMS intervention
Secondary COVID bivalent booster receipt Whether patients receive a bivalent COVID booster at the pharmacy in question 60 days after receiving the SMS/MMS intervention
Secondary COVID bivalent booster receipt Whether patients receive a bivalent COVID booster at the pharmacy in question 90 days after receiving the SMS/MMS intervention
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure